Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Silence Therapeutics Plc ADR (NQ: SLN ) 20.99 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 20.99 Bid (Size) 8.400 (2) Ask (Size) 25.00 (1) Prev. Close 20.99 Today's Range 20.99 - 20.99 52wk Range 4.880 - 27.72 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks July 25, 2024 It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. Via InvestorPlace Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients June 27, 2024 From Silence Therapeutics plc Via Business Wire Performance YTD +13.15% +13.15% 1 Month +10.47% +10.47% 3 Month -4.07% -4.07% 6 Month +11.06% +11.06% 1 Year +252.18% +252.18% More News Read More Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration June 24, 2024 From Silence Therapeutics plc Via Business Wire The Analyst Landscape: 6 Takes On Silence Therapeutics June 20, 2024 Via Benzinga What 7 Analyst Ratings Have To Say About Silence Therapeutics May 17, 2024 Via Benzinga Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock April 22, 2024 Via Benzinga What 4 Analyst Ratings Have To Say About Silence Therapeutics March 13, 2024 Via Benzinga Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) June 20, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Present at Jefferies Global Healthcare Conference May 30, 2024 From Silence Therapeutics plc Via Business Wire SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024 May 16, 2024 Via InvestorPlace Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress May 16, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference April 30, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors April 29, 2024 From Silence Therapeutics plc Via Business Wire 3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 April 11, 2024 Via InvestorPlace Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) April 08, 2024 From Silence Therapeutics plc Via Business Wire 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 Via InvestorPlace These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results March 14, 2024 Via Benzinga What's Going On With Silence Therapeutics Stock Today? March 13, 2024 Via Benzinga Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights March 13, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) March 13, 2024 From Silence Therapeutics plc Via Business Wire Earnings Scheduled For March 13, 2024 March 13, 2024 Via Benzinga Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024 February 28, 2024 From Silence Therapeutics plc Via Business Wire Earnings Scheduled For March 12, 2024 March 12, 2024 Via Benzinga Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial February 23, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Oversubscribed $120 Million Private Placement February 05, 2024 From Silence Therapeutics plc Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
